b-ONE Mobio Total Knee System Revision Cemented Tibial Augments, Stem Extensions and Press-Fit Stem Extensions
B-One Ortho, Corp. · Decision date Sep 8, 2026
What did the FDA decide?
FDA recorded a Substantially Equivalent (SESE) decision for B-One Ortho, Corp.'s K262341 on September 8, 2026. The device name identifies the b-ONE Mobio Total Knee System Revision Cemented Tibial Augments, Stem Extensions and Press-Fit Stem Extensions. The Traditional submission was received July 10, 2026. FDA's database lists classification code JWH, subsequent code MBH and regulation 888.3560, with Orthopedic as the review panel.
The FDA document excerpt describes the submission's purpose as expanding the available sizes of Tibial Stem Extensions. Its sentence stops before the size details are complete, so it does not establish the full added size range here. Another excerpt describes Press-Fit Stem Extensions as optional fixation components. The available text does not identify a predicate device or give complete dimensions, and this explanation does not infer either from the product-family name.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Orthopedic
- Decision date
- Sep 8, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262341
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- B-One Ortho, Corp.
- Product code
- JWH
- Decision code
- SESE
- Decision date
- Sep 8, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, Knee, Patellofemorotibial, Semi-Constrained, Cemented, Polymer/Metal/Polymer.
- Applicant
- B-One Ortho, Corp.
- Product code
- JWH
- FDA device class
- 2
FDA decision timeline
K262341 received
Application receipt date recorded by FDA.
K262341 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code JWH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MicroPort Total Knee SystemK263065 | Suzhou Microport Orthorecon Co., Ltd. | 510(k) clearance | Oct 29, 2026 | FDA |
GMK ExtensionK262057 | Medacta International SA | 510(k) clearance | Sep 15, 2026 | FDA |
GSPE SpacerK260063 | The General Hospital Corporation, d/b/a Massachusetts | 510(k) clearance | Sep 11, 2026 | FDA |
| Suzhou Microport Orthorecon Co., Ltd. | 510(k) clearance | Sep 10, 2026 | FDA | |
ATTUNE Revision Knee SystemK262130 | Depuy Orthopaedics, Inc. | 510(k) clearance | Sep 4, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
B-One Ortho, Corp.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Cedar Knolls, NJ
Sources and methodology
- Original FDA record: K262341
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


